Solana Treasury Funded Company Artelo Biosciences Raises $11 Million

Artelo Biosciences, a company linked to the Solana Treasury, announced a private placement of 3,188,407 common shares at $3.45 per share, raising $11 million total. The company holds 45,883 SOL, according to Strategic Solana Reserve data. The transaction is expected to close around March 30, 2026.

In addition to the share offering, Artelo issued up to 6,376,814 warrants to purchase shares at $3.20 per share. If all warrants are exercised, the total amount raised could reach approximately $20.4 million. The warrants are exercisable immediately and will expire five and one-half years from the effectiveness date of a resale registration statement.

The funds raised will support general corporate purposes and help repay a portion of its outstanding bridge loan. H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction.

Why Did the Stock Surge?

The announcement of the private placement coincided with a 600% surge in ARTL stock price. The jump is likely driven by the company's thin float and investor speculation. While the raise provides immediate liquidity, the sharp price movement raises questions about market dynamics and investor behavior.

The offering highlights Artelo Biosciences' ongoing liquidity needs and its efforts to strengthen its balance sheet. This move could stabilize operations as the company continues its biopharmaceutical development in areas like anorexia, cancer, and dermatology.

What Are the Key Financial Terms of the Offering?

Artelo Biosciences priced the private placement at $3.45 per share, which is close to recent market prices. The company also issued warrants at $3.20 per share, slightly below the share price. The warrants are exercisable immediately and will expire five and one-half years from the effectiveness date of a resale registration statement.

The transaction is expected to close on or about March 30, 2026 according to the announcement. Gross proceeds from the offering are expected to be approximately $11.0 million, with potential additional proceeds of up to $20.4 million if all warrants are exercised.

The private placement is structured as a priced at-the-market offering under Nasdaq rules. This structure allows the company to raise capital efficiently while minimizing market disruption.

What Are the Next Steps for Artelo Biosciences?

The proceeds from the private placement will be used for working capital, general corporate purposes, and the repayment of bridge debt. This move is expected to reduce the company's reliance on short-term financing and improve its financial flexibility.

Artelo Biosciences plans to continue its biopharmaceutical development initiatives, which include programs in anorexia, cancer, and dermatology. The company's Solana holdings of 45,883 SOL provide additional liquidity and diversification.

Investors will be watching how the company allocates the funds and whether it meets its financial goals. The success of the offering could influence future capital-raising activities and investor confidence in the company's strategic direction.